MiR-222 in glioma can regulate cell cycle progression and apoptosis. However, the relationship between miR-222 and Wnt/β-catenin signaling pathway in glioma remains unknown. Here, we found that the Dickkopf-2 gene (DKK2) was a direct target of miR-222 by target prediction analysis and dual luciferase reporter assay. RNA interference silencing of DKK2 proved that miR-222 overexpression led to constitutive activation of β-catenin through inhibition of DKK2 expression in glioma cells. Furthermore, miR-222 siRNA significantly inhibited tumorigenesis in vivo. Finally, Western blot analysis showed that miR-222 could regulate the expression of β-catenin and the downstream genes of Wnt/β-catenin signaling pathway. Taken together, our findings reveal a new regulatory mechanism of miR-222 and suggest that miR-222 might be a potential target in glioma therapy. Abstract MiR-222 in glioma can regulate cell cycle progression and apoptosis. However, the relationship between miR-222 and Wnt/β-catenin signaling pathway in glioma remains unknown. Here, we found that the Dickkopf-2 gene (DKK2) was a direct target of miR-222 by target prediction analysis and dual luciferase reporter assay. RNA interference silencing of DKK2 proved that miR-222 overexpression led to constitutive activation of β-catenin through inhibition of DKK2 expression in glioma cells. Furthermore, miR-222 siRNA significantly inhibited tumorigenesis in vivo. Finally, Western blot analysis showed that miR-222 could regulate the expression of β-catenin and the downstream genes of Wnt/β-catenin signaling pathway. Taken together, our findings reveal a new regulatory mechanism of miR-222 and suggest that miR-222 might be a potential target in glioma therapy.
MicroRNA-222 promotes tumorgenesis via targeting DKK2 and activating the Wnt/β-catenin signaling pathway

Introduction
Gliomas are the most common form of malignancy in the central nervous system [1] . Despite therapeutic advances, the median survival time for high-grade gliomas is only 15 months [2] . Previous studies have suggested that the formation of gliomas is related to the rates of cell proliferation and apoptosis. Therefore, understanding the main regulatory mechanism of this malignancy is the key to developing novel and effective therapeutic strategies for gliomas.
MicroRNAs (miRNAs) are noncoding RNA molecules that regulate the expression of a wide variety of genes through sequence-specific binding to their mRNA targets, resulting in translational inhibition [3] . They have pivotal roles in various physiological and pathological processes, including proliferation and apoptosis [4] . An increasing body of evidence has suggested that the aberrant expression of miRNAs may lead to the development and progression of malignancy [5, 6] . In recent years, miR-222 has been reported to be overexpressed in human carcinomas, including thyroid papillary tumors and glioblastoma [7, 8] . Functional studies have demonstrated that miR-222 may target multiple signaling pathway and genes, such as p27Kip1 and PUMA, to promote the development and progression of malignancy [9, 10] . Thus, miR-222 can be classified as an oncomir, and the decreased expression of miR-222 might be a promising strategy for cancer therapeutics. It has been demonstrated that abnormally high activation of the Wnt/β-catenin pathway is required for the initiation and progression of glioma [11] ; however, until now, functional analysis of miR-222 and the Wnt/β-catenin pathway has not been well-documented.
In the present study, we investigated the potential involvement of miR-222 in glioma. We examined the expression level of miR-222 in glioma cells, and tested its effects on cell growth, apoptosis, and colony formation in vitro and tumorigenesis in vivo. Furthermore, we explored the underlying role of miR-222 in glioma. Finally, we also analyzed the possible relationship between miR-222 and the genes downstream of the Wnt/β-catenin pathway in glioma development and progression. Our study will provide a better understanding of glioma pathogenesis.
Materials and methods Reagents
Antibodies against β-actin, Bcl2, Bax, β-catenin, c-myc, DKK2, and c-Jun were obtained from Santa Cruz Biotechnology Inc. (California, USA). A dual luciferase reporter assay system was obtained from Promega Corporation (Wisconsin, USA). PGL3-promoter, PGL3-basic, and PRL-TK vectors were also purchased from Promega. All other chemicals were purchased from Sigma-Aldrich unless otherwise stated.
Cell lines and cultures
Glioma cell lines, including U251, U87, SHG44, A172, and a human astrocyte cell line (HA) (Cell Bank of Chinese Academy of Science Shanghai China), were cultured in RPMI 1640 medium (Gibco Industries, Inc. Carlsbad, CA) with 10% fetal bovine serum (Gibco Industries, Inc). U87 and U87-miR-222-disrupted fluorescent (EGFP)-labeled cells were developed （Neuron Biotech co., Ltd, Shanghai. China）and are referred to as Control and GR232 for conciseness.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
The rate of proliferation was assessed using the colorimetric MTT assay as described previously [12] Primers of all genes are described in the supplementary data. Data were collected and analyzed by the comparative Ct (threshold cycle) method using GADPH as the reference gene.
Flow cytometric analysis of apoptosis
The extent of apoptosis was measured through the Annexin V-FITC apoptosis detection kit (Invitrogen Corporation, California, USA) according to the manufacturer's instructions. The cells (6 ×10 4 /well) were seeded in six-well plates in antibiotic-free media, followed by transfection with control oligonucleotide (100 nM) or mimics (100 nM) using Lipofectamine 2000 (Invitrogen Corporation, California, USA). After 48 h, the cells were collected, washed with cold PBS twice, and gently resuspended in 400 µL 1*binding buffer. After adding 5 µL of Annexin V-FITC, the cells were gently vortexed and incubated for 10 min at 4 °C in the dark. Then, the tube was incubated with 10 µL of PI for another 5 min at 4 °C in the dark. Finally, the cells were analyzed using a FACScan flow cytometer (Becton Dickinson, New jersey, USA). In Fig.2C , cells in the lower right quadrant represent early apoptosis, and those in the upper right quadrant are representative of late apoptotic cells.
Luciferase activity assay
The 3' UTR of human DKK2 (GeneBank accession number NM_000633) cDNA, containing the putative target sites for miR-222, was amplified by PCR using the following primers: 5'-GATCGCCGTGTAATTCTAGAGTTTCATTGCCCTCT-3' (sense) and 5'-CGTCGATAACTGAAACCAAAGTCAATAGCTGC-3' (anti-sense). Then, it was inserted into the XbaI restriction site, immediately downstream of the luciferase gene in the pGL3-promoter-vector (Promega, Madison, WI). A mutant version with a deletion of 7 bp from a site of perfect complementarity was also generated using the QuikChange II Site-Directed Mutagenesis Kit (Stratagene, LaJolla, CA). Wild-type and mutant inserts were confirmed by sequencing. Twenty-four hours after transfection, the cells were seeded into 96-well plates (8×10 California, USA) according to the manufacturer's protocol. Luciferase activity was measured 48 h post-transfection using the Dual Luciferase Reporter Assay System (Promega Corporation, Wisconsin, USA). Firefly luciferase activity was normalized to renilla luciferase activity for each transfected well. Three independent experiments were performed in triplicate.
Western blot analysis
The U251 and U87 cells were seeded in six-well plates (4 ×10 cells/well) in antibiotic-free media, followed by transfection with control oligonucleotide (100 nM), inhibitor (100 nM), or mimics (100 nM) using Lipofectamine 2000 (Invitrogen Corporation, California, USA). After 48 h of culture, the cells were harvested and homogenized with lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.02% sodium azide, 100 g/mL PMSF, 1 g/mL aprotinin). Total protein extract (40 µg) was separated on 12% SDS-PAGE gels and transferred to nitrocellulose membranes (Millipore, Bedford, MA). After blocking with 5% nonfat dry milk in TBS, the membrane was probed with primary monoclonal antibody specific to DKK2 (1:100; Cell Signaling Technology) which was used as an internal control for protein loading. The membrane was further probed with horseradish peroxidase-conjugated rabbit anti-mouse IgG (1:2,000; Santa Cruz), and the protein bands were visualized using enhanced chemiluminescence (Amersham Pharmacia Corp., Piscataway, NJ). β-Actin was used as a loading control.
Subcutaneous and orthotopic xenografts
For subcutaneous implantation, 5×10 6 Control cells (U87 cells) and GR232 cells (miR-222-disrupted U87 cells) suspended in 100 µl PBS were injected subcutaneously into the flank of BALB/C nude mice (Cancer Institute of the Chinese Academy of Medical Science). The mice were randomly divided into two groups (five mice per group). Tumor growth in mice was detected by the Kodak In-Vivo FX Pro system (Kodak, New York, USA). Tumor volume of xenografts was detected every 5 days over the course of the study with fluorescence signaling. Mice were sacrificed and examined 5 weeks after the subcutaneous implantation. All experiments were carried out under the approval of the Administrative Panel on Laboratory Animal Care of the Xinhua Hospital.
In vivo optical imaging
Prior to in vivo imaging, the mice were anesthetized with Phenobarbital sodium. Fluorescence imaging was obtained with an excitation wavelength of 490nm and emission wavelength of 535nm. Exposure times ranged from 1 to 2 min.
Statistical analysis
Statistical analyses based on the two-tailed Student's t-test were performed using the Statistical Package for the Social Sciences software. Significance was determined at the 95% confidence interval. All data were expressed as the mean ± standard deviation (SD) from a representative experiment.
Results
MiR-222 was overexpressed in glioma cells
The four glioma cell lines (U251, U87, SHG44 and A172) were compared with a human astrocyte cell line (HA) (Fig. 1A) . The miR-222 expression in U251, U87, SHG44 and A172 cells was clearly up-regulated by 50-to 150-fold. The U251 and U87 glioma cell lines, which possessed the highest levels of miR-222 expression among all tested glioma cell lines, were selected for further studies. 3.2. MiR-222 overexpression promoted cell viability and colony formation, but inhibited apoptosis of glioma cells
Given that miR-222 is overexpressed in glioma and that it may act as an oncomiR, we next evaluated the oncogenic function of miR-222 in the U251 and U87 glioma cell lines. Up-regulated miR-222 promoted colony formation, whereas down-regulated miR-222 restrained this activity (Fig. 1B) . MTT assay showed that transfection with miR-222 mimics increased cell survival; conversely, cells transfected with miR-222 inhibitors showed a significant decrease in survival (Fig. 1C) . Next, we used flow cytometry to test the role of miR-222 in apoptosis. Down-regulated miR-222 triggered apoptosis; in contrast, up-regulated miR-222 decreased the number of cells undergoing apoptosis (Fig. 1D). 
miR-222 siRNA significantly inhibited tumorigenesis in vivo
To evaluate the effect of miR-222 in glioma, we constructed EGFP-labeled U87 cells and miR-222-disrupted U87 cells (referred to as control and GR232, respectively). Tumors were generated from the control and GR232 cells by subcutaneous implantation. Tumor volume was measured every 5 days. Tumor growth in the mice was monitored by a live imaging system detecting the fluorescent (EGFP) signals. During the course of the study, miR-222-disrupted U87 cells demonstrated significantly inhibited tumor growth ( Fig. 2A) . All data were presented as the mean ± SD and as an average of three measurements from a representative experiment (p = 0.0079, Mann-Whitney test). Tumor volumes were also measured weekly. Tumors were photographed at the 5th week. When miR-222 was inhibited in EGFP-labeled U87 cells, we found that tumor growth was significantly inhibited (Fig. 2B) .
DKK2 is a direct target gene of miR-222
Using the algorithm Target Scan (http://www.targetscan.org), we found that the inhibitory protein encoded by DKK2 is a target of post-transcriptional repression by miR-222. MiR-222 has 7 nucleotides of the "seed" region which are complementary to the DKK2 3'-UTR (Fig. 3A) , indicating that DKK2 is the potential target of miR-222. Consequently, the down-regulation of miR-222 expression in U251 and U87 cells was concurrent with the up-regulation of DKK2 protein expression. To ascertain whether miR-222 regulates DKK2, we employed a gene overexpression approach to examine the effect of miR-222 on the DKK2 protein. The U251 and U87 cells were transfected with a miR-222 mimics or inhibitor. DKK2 protein expression, determined via Western blot, was down-regulated in miR-222 mimics-transfected cells relative to the control cells. By contrast, DKK2 protein expression was up-regulated in miR-222 inhibitor-transfected cells (Fig. 3B) . To examine whether miR-222 directly targets DKK2, a segment of the DKK2 3'-UTR containing miR-222 binding sites was cloned into a luciferase reporter system. The plasmid lacking the binding sites was used as a positive control of luciferase activity. The resulting reporter vector was transfected into the U87 cells together with increasing concentrations of miR-222. Results showed that miR-222 inhibited luciferase activity in the DKK2 wild-type group. No variation in the luciferase activity was observed when the cells were transfected with the plasmid containing a DKK2 3'-UTR fragment without the miR-222 binding sites (Fig. 3C) . In Fig 3D we show the level of up-regulation or inhibition of miR-222 achieved upon transfection with either the mimics or inhibitor. Hence, these results demonstrate that miR-222 directly inhibits DKK2 expression at the post-transcriptional level through its 3'-UTR. 3.5. Relationship between miR-222 and the Wnt/β-catenin pathway DKK2 is the inhibitor of the Wnt/β-catenin signaling pathway [13] , so we hypothesized that miR-222 might play a role relevant to Wnt/ β-catenin signaling. To test our hypothesis, we detected the β-catenin protein levels by Western blot in miR-222 mimics-and inhibitor-transfected cells. The β-catenin protein level was decreased in miR-222 inhibitor-transfected cells, contrary to the increased β-catenin protein level in miR-222 mimics-transfected cells (Fig. 4A) . These data show that miR-222 functions by targeting the inhibitory protein DKK2, which in turn blocks the Wnt/β-catenin signaling pathway. Furthermore, we detected the genes downstream of the Wnt/β-catenin signaling pathway, including Bcl2, c-myc, and c-Jun. Expression of these genes was tested using Western blot in miR-222 mimics-, control-, and inhibitor-transfected cells. Results showed that down-regulated miR-222 could repress the protein levels of Bcl2, c-myc, and p-c-Jun, but did not affect c-Jun (Fig. 4B) . To determine whether miR-222 functions by targeting DKK2, we inhibited DKK2 expression by siRNA and tested the protein levels of β-catenin, Bcl2, c-myc, and p-c-Jun. We observed up-regulated expression of ß-catenin, Bcl2, and c-myc; in contrast, p-c-Jun expression was down-regulated, suggesting that it is independent of miR-222 inhibition (Fig. 4C) . The protein expression in tumors was detected by Western blot. As shown in Fig. 4D , DKK2 expression increased in GR232 cells in vivo, which also confirmed the in vitro results. These results indicated that miR-222 functioned as an oncomiR by targeting DKK2.
Discussion
In recent years, emerging evidence has demonstrated an important role for miRNAs in regulating human cancers [14] . At least 30% of protein-coding genes in the human genome are regulated by miRNAs [15] . Functional studies have directly documented the potent pro-and anti-tumorigenic activity of specific miRNAs both in vitro and in vivo [16] ; therefore, miRNAs can be classified as oncomirs or tumor-suppressive miRNAs. These miRNAs are associated with tumor cell processes like proliferation, apoptosis, angiogenesis, migration, and metastasis [17] . Recently, it was reported that miR-222 is overexpressed in different kinds of human cancers, including glioblastoma [9, 10] . Several studies have revealed that miR-222 may target multiple signaling pathways, such as the AKT pathway and EGFR signaling pathway, to promote the development and progression of malignancy [18, 19] . However, there has been no functional analysis of miR-222 and the Wnt/β-catenin pathway in glioma.
In the present study, we found that miR-222 was overexpressed in glioma cells (Fig.1A) . Ectopic expression of miR-222 in vitro significantly promoted the proliferation and colony formation of glioma cells, while inhibiting their apoptosis (Fig.1B,C,D) . To evaluate the carcinogenesis of miR-222 in vivo, we injected miR-222-disrupted U87 cells and normal U87 cells into nude mice. The results demonstrated that miR-222-disrupted U87 cells are significantly less tumorigenic than the normal U87 cells in vivo (p=0.0079) (Fig.2) . These findings demonstrated that miR-222 can be classified as an oncomir and might be a promising target for cancer therapeutics. One established characteristic of microRNAs is the ability of a single microRNA to directly target multiple downstream genes [20] . In previous studies, it has been reported that miR-222 can target PUMA to induce cell survival in glioblastoma [10] . Another report demonstrated that miR-222 could target RECK to promote cancer cell proliferation in gastric cancer [21] . These previously reported target genes may also partially explain the relationship between miR-222 and the genes detected in the current study. However, the mechanism of tumorigenesis is so complex that the effect of miR-222 in glioma development and progression remains largely unknown. In the present study, we found by TargetScan that the 3′ UTR of DKK2 is a probable target of miR-222 (Fig.3A) . We further showed by Western blot that miR-222 overexpression resulted in the down-regulation of DKK2 at the protein level, whereas functional inhibition of miR-222 led to DKK2 overexpression; together, these data strongly suggest that DKK2 is regulated by miR-222 in glioma cells (Fig.3B) . A dual luciferase reporter assay also identified DKK2 as a direct target of miR-222. Furthermore, we detected the protein levels of DKK2 in implanted tumors by Western blot; as shown in Fig. 4D , DKK2 expression increased in GR232 cells compared with the control. These results proved that DKK2 was a direct target of miR-222.
As DKK2 is a critical antagonist of the Wnt pathway [22] , and the wnt/β-catenin signaling pathway has been reported to be activated in glioma [23] , we speculated that miR-222 might promote tumorigenesis by regulating Wnt/β-catenin signaling via DKK2. To elucidate the underlying mechanism, we detected the expression levels of β-catenin and the genes downstream of the Wnt/β-catenin signaling pathway, including Bcl2, c-myc, c-Jun and p-c-Jun. The results showed that miR-222 overexpression inhibited the expression of DKK2 proteins, which abrogated the inhibitory effect of DKK2 on Wnt/β-catenin signaling. This phenomenon then led to the disruption of the axin/APC/GSK3 complex, thereby stabilizing β-catenin and permitting its subsequent activation. The activated β-catenin was then translocated into the nucleus, where it in turn activated its downstream effectors and functionally contributed to tumorigenesis [24] . In the present study, we demonstrated for the first time that miR-222 functions as an oncomiR in glioma via targeting DKK2 and activating the Wnt/β-catenin signaling pathway.
Taken together, the results suggest that miR-222 has a crucial role in glioma progression through its target gene, DKK2; this disruption contributes to tumorigenesis via the Wnt/β-catenin signaling pathway. Therefore, miR-222 could be a future therapeutic target for the management of glioma. . Quantification real-time PCR reverse transcription-PCR was done on cDNA which was generated from total RNA. All data were presented as representative of an average of three independent experiments. B. U251 and U87 cells were transfected with a miR-222 mimics, control oligonucleotide, or inhibitor (antisense oligonucleotide-miR-222). Up-regulated miR-222 promoted colony formation, whereas down-regulated miR-222 restrained this activity. C. MiR-222 mimics increased cell survival; conversely, a miR-222 inhibitor significantly decreased survival (n=3; means ± SEM **p<0.01, ***p<0.001 t-test). D. Cell apoptosis was determined by flow cytometry. A significant increase in cell apoptosis was induced by the miR-222 inhibitor compared with the negative control, while the miR-222 mimics group showed a decrease in cell apoptosis. Data are representative of 1 of 3 similar experiments. 
